Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28495861 | 0.95 | TSHR (0.44) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL2776924 | 0.93 | TSHR (0.48) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL588137 | 0.91 | TSHR (0.48) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL301337 | 0.90 | TSHR (0.42) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| Ammonia Solution, Strong SCHEMBL589022 | 0.89 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL588848 | 0.89 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL588940 | 0.89 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL588709 | 0.89 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL28909748 | 0.89 | TSHR (0.45) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL588941 | 0.88 | CA1 (0.39) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114819-B2 | Polymers for oilfield applications | BAKER HUGHES INCORPORATED (US) | 2012-02-14 | — | — | US | disclosed |
| US-8025901-B2 | Bifunctional-modified hydrogels | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100209509-A1 | BIFUNCTIONAL-MODIFIED HYDROGELS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100105580-A1 | Polymers For Oilfield Applications | BJ SERVICES COMPANY (US) | 2010-04-29 | — | — | US | disclosed |
| US-7615593-B2 | Comprises interpenetrating polymer network/matrix (of collagen and/or gelatin) modified with endcapped polyalkylene glycol; drug delivery; for incorporation into bandages, surgical and dental wound packing material, diapers and catamenial devices | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-20060100369-A1 | Bifunctional-modified hydrogels | KAO WEIYUAN J | 2006-05-11 | — | — | US | disclosed |
| US-20050276858-A1 | Bifunctional-modified hydrogels | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | disclosed |
| EP-1423093-A4 | BIFUNCTIONAL-MODIFIED HYDROGELS | WISCONSIN ALUMNI RES FOUND (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1423093-A2 | BIFUNCTIONAL-MODIFIED HYDROGELS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030083389-A1 | Bifunctional-modified hydrogels | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | disclosed |
| WO-2002085419-A2 | BIFUNCTIONAL-MODIFIED HYDROGELS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-0267574-A2 | Heat resistant copolymer composition | Sumitomo Dow Limited (JP) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050276858-A1 | Bifunctional-modified hydrogels | PCNA, CDC25B, ALG1 | TSHR 3688/4885ALDH1A1 281/4885CYP3A4 3418/4885 |
| US-20100209509-A1 | BIFUNCTIONAL-MODIFIED HYDROGELS | PCNA, CDC25B, ALG1 | TSHR 3688/4885ALDH1A1 281/4885CYP3A4 3418/4885 |
| US-20060100369-A1 | Bifunctional-modified hydrogels | PCNA, CDC25B, ALG1 | TSHR 3688/4885ALDH1A1 281/4885CYP3A4 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.